Clinical Trials Logo

Acinetobacter Baumannii Infection clinical trials

View clinical trials related to Acinetobacter Baumannii Infection.

Filter by:
  • None
  • Page 1

NCT ID: NCT04636554 Available - Covid19 Clinical Trials

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Start date: n/a
Phase:
Study type: Expanded Access

Phage Treatment in Covid-19 Patients with Bacterial Co-Infections

NCT ID: NCT03310463 Completed - Clinical trials for Acinetobacter Baumannii Infection

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

Start date: October 3, 2017
Phase: Phase 1
Study type: Interventional

This research project is being conducted to look at the pharmacokinetics (PK; how the human body processes a substance), safety, and tolerability of a single dose of ETX2514 and sulbactam (ETX2514SUL) when concurrently administered by separate intravenous (IV) infusion in participants with various degrees of renal impairment (RI), in participants with end-stage renal disease (ESRD) who are on hemodialysis (HD), and in healthy matched control participants with normal renal function.

NCT ID: NCT02971423 Completed - Clinical trials for Acinetobacter Baumannii Infection

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This research project is being conducted to look at the safety, tolerability, and pharmacokinetics (PK; how the human body processes a substance) of ETX2514 when given to healthy volunteers intravenously as a single dose, and when given as multiple intravenous doses for up to 8 consecutive days. As it is anticipated that ETX2514 could be used as a treatment for Acinetobacter baumannii (a type of bacteria) infections, this project will also look at whether ETX2514 will interact with the current treatments for these infections when they are administered at the same time.

NCT ID: NCT02886637 Completed - Clinical trials for Acinetobacter Baumannii Infection

Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection

Start date: July 2015
Phase: N/A
Study type: Observational

The purpose of the present study is to evaluate the effects of immune function on prognositic outcome in critical ill patients with Acinetobacter baumannii infection.